Alpha Score of 57 reflects moderate overall profile with moderate momentum, moderate value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Regeneron Pharmaceuticals (REGN) continues to demonstrate significant operational scale, highlighted by a robust 99.0% year-over-year revenue growth rate. Despite this top-line expansion, earnings per share growth remains more modest at 8.5%, resulting in a current P/E ratio of 42.71. The company maintains a solid net margin of 31.4%, reflecting disciplined cost management relative to its aggressive revenue trajectory. REGN is currently trading within its 52-week range of $483.07 to $812.27, supported by an Alpha Score of 64.7. This score is underpinned by a strong quality sub-score of 78.5 and a momentum sub-score of 75.5, indicating consistent market interest even as value metrics remain elevated at 60.8. While the substantial revenue growth signals strong market penetration, the disparity between top-line gains and EPS growth suggests that investors are balancing high-growth expectations against the company's current valuation premium. Market participants continue to monitor how the firm sustains these margins while navigating the broader healthcare sector landscape throughout the remainder of the fiscal year. Watch for updates on pipeline developments and margin sustainability in the upcoming quarterly earnings report.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 1 | $771 |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 3 | $2K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 8 | $6K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 8 | $6K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 14 | $11K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 13 | $10K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 9 | $7K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 4 | $3K |
| Apr 1, 26 | Ryan Arthur F | Director | SELL | 40 | $31K |
| Mar 2, 26 | Ryan Arthur F | Director | SELL | 7 | $5K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 684K | $528.17M | NEW |
| Marshall Wace | 479K | $369.46M | NEW |
| Point72 Steve Cohen | 266K | $205.18M | NEW |
| D.E. Shaw David Shaw | 178K | $137.76M | NEW |
| Renaissance Technologies Jim Simons (founder) | 9K | $7.01M | NEW |
| ARK Invest Cathie Wood | 110 | $84.7K | NEW |
Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye diseases such as wet age-related macular degeneration and diabetic macular edema; Dupixent for atopic dermatitis, asthma, and allergic conditions; Libtayo for cutaneous squamous cell carcinoma and other cancers; and Kevzara for rheumatoid arthritis. Regeneron also develops monoclonal and bispecific antibodies through collaborations with partners like Sanofi, and maintains early-stage partnerships in gene editing and RNA interference technologies. The company employs proprietary VelociSuite technologies, including VelocImmune, to accelerate drug development by utilizing genetically humanized mice to produce optimized fully human antibodies. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients across oncology, immunology, ophthalmology, and cardiovascular disease markets globally.
Earnings calendar coming soon. Subscribe to get notified when REGN reports next.
Get earnings alerts →